Generic placeholder image

Current Clinical Pharmacology

Editor-in-Chief

ISSN (Print): 1574-8847
ISSN (Online): 2212-3938

Anacetrapib: A New Weapon Against Dyslipidemia

Author(s): Georgios Aperis, Christos Paliouras, Eirini Tsampikaki, Nikolaos Papakonstantinou and Polichronis Alivanis

Volume 6, Issue 4, 2011

Page: [227 - 235] Pages: 9

DOI: 10.2174/157488411798375949

Price: $65

Abstract

Anacetrapib is a cholesteryl-ester-transfer-protein (CETP) inhibitor, a new class of experimental drugs in the treatment of primary hypercholesterolemia and dyslipidaemia associated with the metabolic syndrome. One of the major advantages of this agent is, apart from the significant decrease in LDL-C it produces a substantial increase in HDL-C. Phase I, II, and III clinical trials have shown that anacetrapib is safe alone or in combination with statins. However, longterm clinical trials are required in order to assess whether it reduces mortality in individuals at high-risk of cardiovascular disease.

Keywords: Anacetrapib, cholesteryl, ester, transfer-protein, inhibitor, Dyslipidemia, cardiovascular disease, cholesterol, blood pressure, plasma


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy